Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 16:00:06 2024-05-16 EDT			5-day change	1st Jan Change
235 ^USD	+0.55%		+2.52%	+1.55%

05-10	Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024	CI
05-07	Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294	MT

IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 02, 2024 at 07:00 am

IQVIA Holdings Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 3,737 million compared to USD 3,652 million a year ago. Net income was USD 288 million compared to USD 289 million a year ago.

Basic earnings per share from continuing operations was USD 1.58 compared to USD 1.56 a year ago. Diluted earnings per share from continuing operations was USD 1.56 compared to USD 1.53 a year ago.

Latest news about Iqvia Holdings Inc.

Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024	05-10	CI
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294	05-07	MT
UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating	05-03	MT
Deutsche Bank Adjusts Price Target on IQVIA Holdings to $275 From $280	05-03	MT
Jefferies Adjusts Price Target on IQVIA to $266 From $281	05-03	MT
Morgan Stanley Adjusts Price Target on IQVIA to $270 From $275	05-03	MT
Truist Adjusts IQVIA Holdings' Price Target to $292 From $297, Keeps Buy Rating	05-03	MT
Baird Adjusts Price Target on IQVIA to $245 From $254	05-03	MT
Leerink Partners Adjusts Price Target on IQVIA to $278 From $290	05-03	MT
Evercore ISI Adjusts Price Target on IQVIA to $250 From $275	05-03	MT
IQVIA trims full-year revenue forecast on stronger dollar	05-02	RE
Transcript : IQVIA Holdings Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
IQVIA Holdings Q1 Adjusted Earnings, Revenue Increase	05-02	MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 Revenue $3.74B, vs. Street Est of $3.71B	05-02	MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 EPS $2.54, vs. Street Est of $2.48	05-02	MT
IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
North American Morning Briefing : Stock Futures -2-	05-02	DJ
Market Share of Celltrion’s Remsima Rises to 74% in Europe	04-24	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	04-22	MT
Mizuho Securities Adjusts IQVIA Holdings' Price Target to $277 From $268, Maintains Buy Rating	04-22	MT
Declaration of Voting Results by IQVIA Holdings	04-17	CI
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	04-09	MT
Iqvia, Salesforce Collaborate to Accelerate Life Sciences Cloud Development	04-08	MT
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud	04-08	CI
Acrux, TruPharma Launch Dapsone 5% Gel in US	04-02	MT

Chart Iqvia Holdings Inc.

Duration

Period

More charts

Company Profile

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Iqvia Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

235 USD

Average target price

271.4 USD

Spread / Average Target

+15.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.55%	42.82B
MODERNA, INC.	+33.37%	50.85B
LONZA GROUP AG	+48.66%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.93%	11.58B

Other Biotechnology & Medical Research